---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-02-14T14:18:16.961493'
end_time: '2026-02-14T14:33:01.110237'
duration_seconds: 884.15
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: TNFAIP3
  gene_symbol: TNFAIP3
  uniprot_accession: P21580
  protein_description: 'RecName: Full=Tumor necrosis factor alpha-induced protein
    3; Short=TNF alpha-induced protein 3; EC=2.3.2.-; EC=3.4.19.12 {ECO:0000269|PubMed:14748687,
    ECO:0000269|PubMed:17961127, ECO:0000269|PubMed:18164316, ECO:0000269|PubMed:23827681,
    ECO:0000269|PubMed:27732584}; AltName: Full=OTU domain-containing protein 7C;
    AltName: Full=Putative DNA-binding protein A20; AltName: Full=Zinc finger protein
    A20; Contains: RecName: Full=A20p50; Contains: RecName: Full=A20p37;'
  gene_info: Name=TNFAIP3; Synonyms=OTUD7C;
  organism_full: Homo sapiens (Human).
  protein_family: Belongs to the peptidase C64 family. .
  protein_domains: OTU_Deubiquitinase. (IPR051346); OTU_dom. (IPR003323); Znf_A20.
    (IPR002653); OTU (PF02338); zf-A20 (PF01754)
provider_config:
  timeout: 600
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
citation_count: 18
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P21580
- **Protein Description:** RecName: Full=Tumor necrosis factor alpha-induced protein 3; Short=TNF alpha-induced protein 3; EC=2.3.2.-; EC=3.4.19.12 {ECO:0000269|PubMed:14748687, ECO:0000269|PubMed:17961127, ECO:0000269|PubMed:18164316, ECO:0000269|PubMed:23827681, ECO:0000269|PubMed:27732584}; AltName: Full=OTU domain-containing protein 7C; AltName: Full=Putative DNA-binding protein A20; AltName: Full=Zinc finger protein A20; Contains: RecName: Full=A20p50; Contains: RecName: Full=A20p37;
- **Gene Information:** Name=TNFAIP3; Synonyms=OTUD7C;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the peptidase C64 family. .
- **Key Domains:** OTU_Deubiquitinase. (IPR051346); OTU_dom. (IPR003323); Znf_A20. (IPR002653); OTU (PF02338); zf-A20 (PF01754)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "TNFAIP3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'TNFAIP3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **TNFAIP3** (gene ID: TNFAIP3, UniProt: P21580) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** P21580
- **Protein Description:** RecName: Full=Tumor necrosis factor alpha-induced protein 3; Short=TNF alpha-induced protein 3; EC=2.3.2.-; EC=3.4.19.12 {ECO:0000269|PubMed:14748687, ECO:0000269|PubMed:17961127, ECO:0000269|PubMed:18164316, ECO:0000269|PubMed:23827681, ECO:0000269|PubMed:27732584}; AltName: Full=OTU domain-containing protein 7C; AltName: Full=Putative DNA-binding protein A20; AltName: Full=Zinc finger protein A20; Contains: RecName: Full=A20p50; Contains: RecName: Full=A20p37;
- **Gene Information:** Name=TNFAIP3; Synonyms=OTUD7C;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Belongs to the peptidase C64 family. .
- **Key Domains:** OTU_Deubiquitinase. (IPR051346); OTU_dom. (IPR003323); Znf_A20. (IPR002653); OTU (PF02338); zf-A20 (PF01754)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "TNFAIP3" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'TNFAIP3' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **TNFAIP3** (gene ID: TNFAIP3, UniProt: P21580) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan and verification
- Identity check: The target is human TNFAIP3 (A20), UniProt P21580. Literature consistently describes A20 as an OTU-family deubiquitinase with seven C‑terminal zinc fingers (ZnFs), functioning as a ubiquitin-editing enzyme in human innate/adaptive immune signaling, matching the UniProt description and domain architecture (OTU DUB; ZnF, including ZnF7) (khouri2023acriticalregion pages 1-2, bagyinszky2024geneticmutationsassociated pages 1-3, khouri2023acriticalregion pages 18-18). 

Comprehensive research report on TNFAIP3 (A20; UniProt P21580)

1) Key concepts and definitions with current understanding
- Molecular identity and domains: A20 (TNFAIP3) encodes a ubiquitin-editing enzyme with an N‑terminal OTU deubiquitinase domain and seven C‑terminal zinc-finger domains. The OTU catalyzes isopeptidase cleavage of polyubiquitin chains; ZnF4 contributes to E3/ubiquitin-editing functions, and ZnF7 binds linear (M1) ubiquitin chains, collectively enabling negative regulation of NF‑κB and cell-death pathways (e.g., TNFR, TLR) (eLife, 2023-06-06, https://doi.org/10.7554/eLife.81280; IJMS, 2024-07-24, https://doi.org/10.3390/ijms25158275) (khouri2023acriticalregion pages 1-2, bagyinszky2024geneticmutationsassociated pages 1-3, khouri2023acriticalregion pages 18-18).
- Core function: A20 terminates inflammatory signaling by editing ubiquitin chains on key adaptor/kinase substrates and by non-enzymatic ubiquitin-binding actions, thereby restraining IKK activation, NF‑κB nuclear translocation, and downstream cytokine production (Science Advances, 2024-08-21, https://doi.org/10.1126/sciadv.adl3975; IJMS, 2024-06-18, https://doi.org/10.3390/ijms25126628) (schultheiss2024a20haploinsufficiencydisturbs pages 1-2, kommer2024a20inkidney pages 10-12).
- Disease concept: Heterozygous loss-of-function variants in TNFAIP3 cause A20 haploinsufficiency (HA20), an autosomal-dominant autoinflammatory disease with Behçet-like mucocutaneous ulcers, gastrointestinal, musculoskeletal, and other systemic features (IJMS, 2024-07-24, https://doi.org/10.3390/ijms25158275; eLife, 2023-06-06, https://doi.org/10.7554/eLife.81280) (bagyinszky2024geneticmutationsassociated pages 16-17, khouri2023acriticalregion pages 1-2, bagyinszky2024geneticmutationsassociated pages 21-22).

2) Biochemistry and mechanism: enzymatic activities, substrates, and pathway roles
- Deubiquitinase specificity: The OTU domain contains catalytic residues (e.g., Cys103, His256) and can cleave Lys63- and Lys48-linked chains on receptor-proximal adaptors to halt signaling. Reviews summarizing enzymology and structural work support K63-directed DUB activity central to dampening NF‑κB; A20’s ZnF7 binds M1-linked chains to further modulate signaling complexes (IJMS, 2024-07-24, https://doi.org/10.3390/ijms25158275; eLife, 2023-06-06, https://doi.org/10.7554/eLife.81280) (bagyinszky2024geneticmutationsassociated pages 1-3, khouri2023acriticalregion pages 18-18).
- Ubiquitin editing/E3 roles: A20 exhibits “ubiquitin-editing” by removing K63 chains and facilitating K48-linked ubiquitylation on substrates, promoting proteasomal turnover and pathway shutdown; phosphorylation by IKKβ also modulates A20 activity and interactions at IKK/NEMO (IJMS, 2024-06-18, https://doi.org/10.3390/ijms25126628) (kommer2024a20inkidney pages 10-12).
- Key substrates and complexes: Substrates include RIPK1 (RIP1), TRAF6, and NEMO/IKKγ. A20 and its cofactors (e.g., ABIN1) engage the TNFR/TLR signalosomes to suppress IKK phosphorylation and NF‑κB activation, and to modulate cell-death checkpoints (apoptosis/necroptosis) (eLife, 2023-06-06, https://doi.org/10.7554/eLife.81280; IJMS, 2024-06-18, https://doi.org/10.3390/ijms25126628) (khouri2023acriticalregion pages 1-2, kommer2024a20inkidney pages 10-12).
- Inflammasome and innate pathways: A20 constrains NLRP3 inflammasome activation; deficiency increases pro‑inflammatory cytokines (IL‑1β, IL‑6, TNF, IL‑18) and is linked to enhanced inflammasome activity in HA20. Reviews highlight A20’s suppression of NLRP3 formation and general restraint of innate pathways downstream of TLR/TNFR (IJMS, 2024-07-24, https://doi.org/10.3390/ijms25158275) (bagyinszky2024geneticmutationsassociated pages 21-22, bagyinszky2024geneticmutationsassociated pages 16-17).
- Cellular localization: A20 functions at receptor-proximal cytoplasmic signaling complexes (e.g., recruitment by NEMO/IKKγ to IKK complexes) consistent with its role in editing ubiquitin chains on RIPK1/TRAF6/NEMO and terminating cytosolic NF‑κB signaling (IJMS, 2024-06-18, https://doi.org/10.3390/ijms25126628) (kommer2024a20inkidney pages 10-12).

3) Regulation of TNFAIP3 (A20)
- Transcriptional induction: TNFAIP3 is a rapid, NF‑κB–inducible gene and a canonical negative feedback regulator induced by TNF and other inflammatory stimuli (Science Advances, 2024-08-21, https://doi.org/10.1126/sciadv.adl3975; IJMS, 2024-06-18, https://doi.org/10.3390/ijms25126628) (schultheiss2024a20haploinsufficiencydisturbs pages 1-2, kommer2024a20inkidney pages 10-12).
- Post-translational control: A20 is regulated by phosphorylation (IKKβ), domain-specific ubiquitin binding (ZnF7 to M1 chains), and protein stability. 2023 work pinpointed missense variants that destabilize the OTU domain, leading to enhanced proteasomal degradation and loss of function (eLife, 2023-06-06, https://doi.org/10.7554/eLife.81280) (kommer2024a20inkidney pages 10-12, khouri2023acriticalregion pages 1-2).

4) Disease genetics: variants, critical regions, and cohort data
- HA20 genetics: Pathogenic TNFAIP3 variants are predominantly truncating (nonsense/frameshift) but also include splice and missense alleles across OTU and ZnF domains. Missense variants in the OTU domain can destabilize A20 (e.g., p.Leu236Pro), impair DUB function toward TRAF6, and diminish NF‑κB inhibition. Structure-informed analysis delineates a pathogenicity-sensitive region in the OTU core (eLife, 2023-06-06, https://doi.org/10.7554/eLife.81280) (khouri2023acriticalregion pages 1-2, khouri2023acriticalregion pages 17-18).
- Phenotypic spectrum and biomarkers: HA20 presents with Behçet-like ulcers, fever, arthritis/arthralgia, gastrointestinal involvement, and variable autoimmunity; patients often exhibit elevated pro-inflammatory cytokines (e.g., IL‑1β, TNF‑α, IL‑6, IL‑18) (IJMS, 2024-07-24, https://doi.org/10.3390/ijms25158275) (bagyinszky2024geneticmutationsassociated pages 16-17, bagyinszky2024geneticmutationsassociated pages 21-22).
- 2024 cohort evidence: In a Science Advances study of 34 HA20 patients, heterozygous TNFAIP3 loss skewed B/T‑cell repertoires toward self‑reactive antigen receptors typical of lymphoma, driven by a TNF/A20/NF‑κB feed‑forward loop. Anti‑TNF therapy reversed the skewing, but some cases progressed to overt lymphoma, underscoring cancer risk and therapeutic modulation of immune homeostasis (Science Advances, 2024-08-21, https://doi.org/10.1126/sciadv.adl3975) (schultheiss2024a20haploinsufficiencydisturbs pages 1-2).

5) Recent developments and latest research (2023–2024)
- Missense interpretation and OTU critical region: 2023 eLife work established functional assays and structural modeling to classify OTU missense variants causing HA20, revealing a destabilization hotspot (Leu236 and interacting residues) that compromises TRAF6 deubiquitination and NF‑κB suppression (eLife, 2023-06-06, https://doi.org/10.7554/eLife.81280) (khouri2023acriticalregion pages 1-2).
- Linear ubiquitin recognition: Continued consolidation of ZnF7’s role in recognizing M1 chains has refined the non‑enzymatic inhibition model, integrating ubiquitin binding with enzymatic editing to terminate signaling (eLife, 2023-06-06, https://doi.org/10.7554/eLife.81280) (khouri2023acriticalregion pages 18-18).
- Immune repertoire and lymphomagenesis risk in HA20: The 2024 Science Advances cohort connected germline A20 haploinsufficiency with skewed, self‑reactive lymphocyte repertoires and pre‑lymphoma transcriptional signatures, reversible with anti‑TNF, providing translational insight into surveillance and therapy in HA20 (Science Advances, 2024-08-21, https://doi.org/10.1126/sciadv.adl3975) (schultheiss2024a20haploinsufficiencydisturbs pages 1-2).

6) Current applications and real-world implementations
- Diagnostics: Genetic testing of TNFAIP3 is recommended when patients display early‑onset autoinflammatory disease with Behçet-like features or multisystem autoimmunity; missense variants require functional assessment (NF‑κB reporter assays, protein stability, DUB activity) and structure-informed interpretation to confirm pathogenicity (eLife, 2023-06-06, https://doi.org/10.7554/eLife.81280; IJMS, 2024-07-24, https://doi.org/10.3390/ijms25158275) (khouri2023acriticalregion pages 1-2, bagyinszky2024geneticmutationsassociated pages 21-22).
- Therapeutic management of HA20: Case series and reviews report variable responses to glucocorticoids, colchicine, methotrexate, IVIG, TNF inhibitors (infliximab, adalimumab, etanercept), IL‑1 blockade (anakinra/canakinumab), and JAK inhibition (e.g., baricitinib), with anti‑TNF shown to reverse disease‑specific immune repertoire skewing in 2024 cohort work. Treatment is individualized; anti‑TNF is frequently effective, and JAK inhibition can help in interferon‑skewed disease. Hematopoietic stem cell transplantation (HSCT) has been used in refractory cases (IJMS, 2024-07-24, https://doi.org/10.3390/ijms25158275; Science Advances, 2024-08-21, https://doi.org/10.1126/sciadv.adl3975) (bagyinszky2024geneticmutationsassociated pages 21-22, schultheiss2024a20haploinsufficiencydisturbs pages 1-2).

7) Expert opinions and authoritative analyses
- Authoritative mechanistic synthesis: Peer‑reviewed domain-leading sources emphasize A20’s dual enzymatic (OTU DUB) and non‑enzymatic (linear ubiquitin binding via ZnF7) activities as central to immune homeostasis. Expert consensus underscores A20 as a hub integrating ubiquitin editing with suppression of IKK/NF‑κB signaling and modulation of RIPK1‑dependent cell-death checkpoints (eLife, 2023-06-06, https://doi.org/10.7554/eLife.81280; Science Advances, 2024-08-21, https://doi.org/10.1126/sciadv.adl3975) (khouri2023acriticalregion pages 1-2, schultheiss2024a20haploinsufficiencydisturbs pages 1-2).
- Translational perspective: 2024 analyses connect clinical phenotypes, repertoire skewing, and lymphoma risk with a TNF/A20/NF‑κB loop, providing a rationale for TNF blockade in HA20 and for vigilant malignancy surveillance (Science Advances, 2024-08-21, https://doi.org/10.1126/sciadv.adl3975) (schultheiss2024a20haploinsufficiencydisturbs pages 1-2).

8) Quantitative data and recent statistics
- Cohort size and modulation by therapy: In a 2024 HA20 cohort (n=34), anti‑TNF reversed repertoire skewing toward self‑reactive B/T cells; nevertheless, progression to lymphoma occurred in some patients, highlighting benefit and residual risk (Science Advances, 2024-08-21, https://doi.org/10.1126/sciadv.adl3975) (schultheiss2024a20haploinsufficiencydisturbs pages 1-2).
- Variant classes and clinical heterogeneity: Reviews compile dozens of truncating and missense TNFAIP3 variants across OTU and ZnF domains with reported cytokine elevations (e.g., IL‑1β, IFN‑γ, TNF‑α, IL‑6, IL‑18) and broad autoinflammatory/autoimmune spectra; however, pooled response rates are heterogeneous and not uniformly quantified across studies (IJMS, 2024-07-24, https://doi.org/10.3390/ijms25158275) (bagyinszky2024geneticmutationsassociated pages 16-17, bagyinszky2024geneticmutationsassociated pages 21-22).

9) Summary of primary function, pathways, and localization
- Primary molecular function: A20 is a ubiquitin-editing protein that deubiquitinates K63/K48 chains (OTU domain) and engages E3/editing and ubiquitin-binding functions via ZnF domains (notably ZnF4 and ZnF7) to terminate receptor-proximal signaling. Canonical substrates include RIPK1, TRAF6, and NEMO/IKKγ at TNFR/TLR complexes. This curbs IKK phosphorylation, NF‑κB activation, and downstream cytokines; it also intersects with RIPK1-dependent death checkpoints and restrains NLRP3 inflammasome activation (eLife, 2023-06-06, https://doi.org/10.7554/eLife.81280; IJMS, 2024-06-18, https://doi.org/10.3390/ijms25126628; IJMS, 2024-07-24, https://doi.org/10.3390/ijms25158275) (khouri2023acriticalregion pages 1-2, kommer2024a20inkidney pages 10-12, bagyinszky2024geneticmutationsassociated pages 21-22).
- Site of action: Cytoplasmic signaling complexes downstream of TNFR and TLR pathways, with recruitment via NEMO/IKKγ and ABIN cofactors, consistent with biochemical editing of ubiquitin chains on RIPK1/TRAF6/NEMO to terminate NF‑κB signaling (IJMS, 2024-06-18, https://doi.org/10.3390/ijms25126628) (kommer2024a20inkidney pages 10-12).

Limitations and open areas
- Some desired 2023–2024 structural and therapeutic statistics (e.g., national HA20 treatment response rates, chain-type kinetic parameters, cGAS–STING interactions) were not available in the cited excerpts. Where mechanistic inferences are presented, they reflect convergent findings from the peer‑reviewed sources above (kommer2024a20inkidney pages 10-12, khouri2023acriticalregion pages 1-2, bagyinszky2024geneticmutationsassociated pages 1-3, khouri2023acriticalregion pages 18-18, bagyinszky2024geneticmutationsassociated pages 21-22, schultheiss2024a20haploinsufficiencydisturbs pages 1-2).

References

1. (khouri2023acriticalregion pages 1-2): Elma El Khouri, Farah Diab, Camille Louvrier, Eman Assrawi, Aphrodite Daskalopoulou, Alexandre Nguyen, William Piterboth, Samuel Deshayes, Alexandra Desdoits, Bruno Copin, Florence Dastot Le Moal, Sonia Athina Karabina, Serge Amselem, Achille Aouba, and Irina Giurgea. A critical region of a20 unveiled by missense tnfaip3 variations that lead to autoinflammation. eLife, Jun 2023. URL: https://doi.org/10.7554/elife.81280, doi:10.7554/elife.81280. This article has 11 citations and is from a domain leading peer-reviewed journal.

2. (bagyinszky2024geneticmutationsassociated pages 1-3): Eva Bagyinszky and Seong Soo A. An. Genetic mutations associated with tnfaip3 (a20) haploinsufficiency and their impact on inflammatory diseases. International Journal of Molecular Sciences, 25:8275, Jul 2024. URL: https://doi.org/10.3390/ijms25158275, doi:10.3390/ijms25158275. This article has 19 citations and is from a poor quality or predatory journal.

3. (khouri2023acriticalregion pages 18-18): Elma El Khouri, Farah Diab, Camille Louvrier, Eman Assrawi, Aphrodite Daskalopoulou, Alexandre Nguyen, William Piterboth, Samuel Deshayes, Alexandra Desdoits, Bruno Copin, Florence Dastot Le Moal, Sonia Athina Karabina, Serge Amselem, Achille Aouba, and Irina Giurgea. A critical region of a20 unveiled by missense tnfaip3 variations that lead to autoinflammation. eLife, Jun 2023. URL: https://doi.org/10.7554/elife.81280, doi:10.7554/elife.81280. This article has 11 citations and is from a domain leading peer-reviewed journal.

4. (schultheiss2024a20haploinsufficiencydisturbs pages 1-2): Christoph Schultheiß, Lisa Paschold, Alma Nazlie Mohebiany, Moritz Escher, Yogita Mallu Kattimani, Melanie Müller, Paul Schmidt-Barbo, Anna Mensa-Vilaró, Juan Ignacio Aróstegui, Guilaine Boursier, Claire de Moreuil, Timo Hautala, Edith Willscher, Hanna Jonas, Namuun Chinchuluun, Bianca Grosser, Bruno Märkl, Wolfram Klapper, Prasad Thomas Oommen, Katharina Gössling, Katrin Hoffmann, Gisa Tiegs, Felix Czernilofsky, Sascha Dietrich, Alexandra Freeman, Daniella M. Schwartz, Ari Waisman, Ivona Aksentijevich, and Mascha Binder. A20 haploinsufficiency disturbs immune homeostasis and drives the transformation of lymphocytes with permissive antigen receptors. Science Advances, Aug 2024. URL: https://doi.org/10.1126/sciadv.adl3975, doi:10.1126/sciadv.adl3975. This article has 12 citations and is from a highest quality peer-reviewed journal.

5. (kommer2024a20inkidney pages 10-12): Andreas Kommer, Myriam Meineck, Paul Classen, and Julia Weinmann-Menke. A20 in kidney transplantation and autoimmunity. International Journal of Molecular Sciences, 25:6628, Jun 2024. URL: https://doi.org/10.3390/ijms25126628, doi:10.3390/ijms25126628. This article has 2 citations and is from a poor quality or predatory journal.

6. (bagyinszky2024geneticmutationsassociated pages 16-17): Eva Bagyinszky and Seong Soo A. An. Genetic mutations associated with tnfaip3 (a20) haploinsufficiency and their impact on inflammatory diseases. International Journal of Molecular Sciences, 25:8275, Jul 2024. URL: https://doi.org/10.3390/ijms25158275, doi:10.3390/ijms25158275. This article has 19 citations and is from a poor quality or predatory journal.

7. (bagyinszky2024geneticmutationsassociated pages 21-22): Eva Bagyinszky and Seong Soo A. An. Genetic mutations associated with tnfaip3 (a20) haploinsufficiency and their impact on inflammatory diseases. International Journal of Molecular Sciences, 25:8275, Jul 2024. URL: https://doi.org/10.3390/ijms25158275, doi:10.3390/ijms25158275. This article has 19 citations and is from a poor quality or predatory journal.

8. (khouri2023acriticalregion pages 17-18): Elma El Khouri, Farah Diab, Camille Louvrier, Eman Assrawi, Aphrodite Daskalopoulou, Alexandre Nguyen, William Piterboth, Samuel Deshayes, Alexandra Desdoits, Bruno Copin, Florence Dastot Le Moal, Sonia Athina Karabina, Serge Amselem, Achille Aouba, and Irina Giurgea. A critical region of a20 unveiled by missense tnfaip3 variations that lead to autoinflammation. eLife, Jun 2023. URL: https://doi.org/10.7554/elife.81280, doi:10.7554/elife.81280. This article has 11 citations and is from a domain leading peer-reviewed journal.

## Citations

1. khouri2023acriticalregion pages 1-2
2. khouri2023acriticalregion pages 18-18
3. bagyinszky2024geneticmutationsassociated pages 1-3
4. bagyinszky2024geneticmutationsassociated pages 16-17
5. bagyinszky2024geneticmutationsassociated pages 21-22
6. khouri2023acriticalregion pages 17-18
7. https://doi.org/10.7554/eLife.81280;
8. https://doi.org/10.3390/ijms25158275
9. https://doi.org/10.1126/sciadv.adl3975;
10. https://doi.org/10.3390/ijms25126628
11. https://doi.org/10.3390/ijms25158275;
12. https://doi.org/10.7554/eLife.81280
13. https://doi.org/10.1126/sciadv.adl3975
14. https://doi.org/10.3390/ijms25126628;
15. https://doi.org/10.7554/elife.81280,
16. https://doi.org/10.3390/ijms25158275,
17. https://doi.org/10.1126/sciadv.adl3975,
18. https://doi.org/10.3390/ijms25126628,